Skip to main content
. 2021 Jul 20;13(14):3630. doi: 10.3390/cancers13143630

Table 2.

Common adverse events (AE) seen in all five presented patients following treatment with lenvatinib plus pembrolizumab. The numbers indicate the grade of each AE in each specific patient.

Case No. Diarrhea Fatigue Hypothyroidism Hypertension Weight Loss
1 2 1 1 0 0
2 2 1 0 1 1
3 0 2 0 1 1
4 0 1 0 0 1
5 0 1 1 1 0